Literature DB >> 24047722

MRI in the evaluation of breast cancer patient response to neoadjuvant chemotherapy: predictive factors for breast conservative surgery.

Mirjan M Nadrljanski1, Zorica C Miloševic, Vesna Plešinac-Karapandžic, Ružica Maksimovic.   

Abstract

PURPOSE: We aimed to prospectively assess the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in the evaluation of predictive factors for breast conservative surgery during neoadjuvant chemotherapy.
MATERIALS AND METHODS: Sixty-six patients were evaluated before the first treatment cycle, after the second cycle, and upon the completion of neoadjuvant chemotherapy according to largest tumor diameter, tumor volume, postcontrast enhancement, and tumor regression pattern. The patients were divided into responders (pathologic complete and near complete response) and nonresponders. Each subgroup was re-evaluated according to morphokinetic criteria for identification of candidates for breast conservative surgery.
RESULTS: In responders (n=27), the lesion size upon the completion of neoadjuvant chemotherapy was significantly smaller compared to nonresponders (1.5 ± 0.6 vs. 3.2 ± 0.9 cm; P < 0.001), as was the volume (1.2 vs. 11.0 cm(3); P < 0.001). The measured lesion size did not differ from the histologic size (1.5 ± 0.6 vs. 1.2 ± 0.6 cm; P = 0.09) and had a high correlation (r=0.93). In responders, the following parameters were significantly different before and after neoadjuvant chemotherapy: size (3.6 ± 1.4 to 1.5 ± 0.6 cm; P < 0.001), volume (17.6 to 1.2 cm(3); P < 0.001), predominant concentric regression, plateau and continuous time-intensity curves (P < 0.001). DCE-MRI has the sensitivity of 87% and the accuracy of 77% to identify candidates for breast conservative surgery.
CONCLUSION: Selected morphokinetic DCE-MRI parameters may contribute to the multidisciplinary decision when considering the selection of candidates for breast conservative surgery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24047722     DOI: 10.5152/dir.2013.13201

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  7 in total

1.  Dynamic Contrast-Enhanced Magnetic Resonance Imaging in the Assessment of Inflammatory Breast Cancer Prior to and After Neoadjuvant Treatment.

Authors:  Dominique J P van Uden; J Hans W de Wilt; Carla Meeuwis; Charlotte F J M Blanken-Peeters; Ritse M Mann
Journal:  Breast Care (Basel)       Date:  2017-08-29       Impact factor: 2.860

2.  Relating Doses of Contrast Agent Administered to TIC and Semi-Quantitative Parameters on DCE-MRI: Based on a Murine Breast Tumor Model.

Authors:  Menglin Wu; Li Lu; Qi Zhang; Qi Guo; Feixiang Zhao; Tongwei Li; Xuening Zhang
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

3.  Breast Dynamic Contrast Enhanced MRI: Fibrocystic Changes Presenting as a Non-mass Enhancement Mimicking Malignancy.

Authors:  Zorica C Milosevic; Mirjan M Nadrljanski; Zorka M Milovanovic; Nina Z Gusic; Slavko S Vucicevic; Olga S Radulovic
Journal:  Radiol Oncol       Date:  2017-05-07       Impact factor: 2.991

4.  Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted magnetic resonance imaging for predicting the response of locally advanced breast cancer to neoadjuvant therapy: a meta-analysis.

Authors:  John Virostko; Allison Hainline; Hakmook Kang; Lori R Arlinghaus; Richard G Abramson; Stephanie L Barnes; Jeffrey D Blume; Sarah Avery; Debra Patt; Boone Goodgame; Thomas E Yankeelov; Anna G Sorace
Journal:  J Med Imaging (Bellingham)       Date:  2017-11-24

5.  Can Multi-Parametric MR Based Approach Improve the Predictive Value of Pathological and Clinical Therapeutic Response in Breast Cancer Patients?

Authors:  Uma Sharma; Khushbu Agarwal; Rani G Sah; Rajinder Parshad; Vurthaluru Seenu; Sandeep Mathur; Siddhartha D Gupta; Naranamangalam R Jagannathan
Journal:  Front Oncol       Date:  2018-08-15       Impact factor: 6.244

6.  DCE-MRI and parametric imaging in monitoring response to neoadjuvant chemotherapy in breast carcinoma: a preliminary report.

Authors:  Anjna Sharma; Sanjiv Sharma; Shikha Sood; Rajeev K Seam; Mukesh Sharma; Vikas Fotedar
Journal:  Pol J Radiol       Date:  2018-05-18

7.  Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients.

Authors:  Alberto Bouzón; Benigno Acea; Rafaela Soler; Ángela Iglesias; Paz Santiago; Joaquín Mosquera; Lourdes Calvo; Teresa Seoane-Pillado; Alejandra García
Journal:  Radiol Oncol       Date:  2016-02-16       Impact factor: 2.991

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.